Position of the Transparency Council – Tagrisso (osimertinib)
At its meeting on 14 April 2025, the Transparency Council adopted position No. 42/2025 on the evaluation of a medicinal product Tagrisso (osimertinib) under drug program B.6. “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)